I n 1965, Hakim and Adams described a syndrome of symptomatic hydrocephalus with a normal CSF pressure that presents with gait disturbance, dementia, and incontinence without overt signs and symptoms of elevated intracranial pressure (ICP). 17 They called it normal pressure hydrocephalus (NPH) and found that it was a "treatable syndrome" with the performance of neurosurgical shunting procedures. 1 Further studies have confirmed these findings and have shown that in spite of a normal CSF pressure approximately 50% of patients with NPH AbbreviAtioNs CVD = cerebrovascular disease; ICH = intracerebral hemorrhage; ICP = intracranial pressure; LP = lumboperitoneal; NPH, iNPH, sNPH = normal pressure hydrocephalus, idiopathic NPH, secondary NPH; SAH = subarachnoid hemorrhage; VA = ventriculoatrial; VP = ventriculoperitoneal. obJeCtive There are several etiologies that can lead to the development of secondary normal pressure hydrocephalus (sNPH). The aim of this study was to evaluate the etiology, diagnosis, treatment, and outcome in patients with sNPH and to highlight important differences between the separate etiologies. MethoDs A comprehensive review of the literature was performed to identify studies conducted between 1965 and 2015 that included data regarding the etiology, treatment, diagnosis, and outcome in patients with sNPH. Sixty-four studies with a total of 1309 patients were included. The inclusion criteria of this study were articles that were written in English, included more than 2 patients with the diagnosis of sNPH, and contained data regarding the etiology, diagnosis, treatment, or outcome of NPH. The most common assessment of clinical improvement was based on the Stein and Langfitt grading scale or equivalent improvement on other alternative ordinal grading scales. resUlts The main etiologies of sNPH were subarachnoid hemorrhage (SAH) in 46.5%, head trauma in 29%, intracranial malignancies in 6.2%, meningoencephalitis in 5%, and cerebrovascular disease in 4.5% of patients. In 71.9% of patients the sNPH was treated with ventriculoperitoneal shunt placement, and 24.4% had placement of a ventriculoatrial shunt. Clinical improvement after shunt placement was reported in 74.4% and excellent clinical improvement in 58% of patients with sNPH. The mean follow-up period after shunt placement was 13 months. Improvement was seen in 84.2% of patients with SAH, 83% of patients with head trauma, 86.4% of patients with brain tumors, 75% of patients with meningoencephalitis, and 64.7% of patients with NPH secondary to stroke. CoNClUsioNs Secondary NPH encompasses a diverse group of clinical manifestations associated with a subset of patients with acquired hydrocephalus. The most common etiologies of sNPH include SAH and traumatic brain injury. Secondary NPH does indeed exist, and should be differentiated from idiopathic NPH based on outcome and on clinical, pathophysiological, and epidemiological characteristics, but should not be considered as a separate entity.
Many articles have described the diagnosis and management of NPH and the predictive tests used for selecting the most appropriate candidates for shunt placement. In 2005, Marmarou and colleagues published guidelines for the diagnosis and management of iNPH and emphasized the importance of distinguishing between iNPH and sNPH.
3, 28, 34, 35, 55 Because sNPH is so heterogeneous with regard to pathology, diagnosis, treatment, and outcome, it is not clear if the term "secondary normal pressure hydrocephalus" should be used to encompass such a wide array of entities and whether unifying guidelines should be made for the diagnosis and management of sNPH. The aim of this review study was to evaluate the etiology, diagnosis, treatment, and outcome in patients with sNPH and to highlight important differences among the separate etiologies. We also sought to answer the following questions: What are the most common etiologies of sNPH? What are the treatments used to manage it? How successful are the treatments?
Methods
A comprehensive review of the literature was performed using the key words "secondary normal pressure hydrocephalus," "normal pressure hydrocephalus," "NPH," "hemorrhage and normal pressure hydrocephalus," "trauma and normal pressure hydrocephalus," "meningitis and normal pressure hydrocephalus," "tumor and normal pressure hydrocephalus," and "stroke and normal pressure hydrocephalus." These terms were used to conduct searches in the following databases: PubMed, Ovid, and Scopus. The databases were last queried on July 1, 2015. The inclusion criteria of this study were articles published between 1965 and 2015, written in English, including more than 2 patients with the diagnosis of sNPH, and containing data regarding the etiology, diagnosis, treatment, or outcome of NPH. The exclusion criteria were the following: case reports, technical notes, review articles, and articles not written in English. Studies that included sNPH cases but did not elaborate on etiology, treatment, or outcome were excluded. Despite the methodological limitations, all publications meeting these criteria were included due to the paucity of research papers dealing with the topic of sNPH. Data regarding etiology, treatment, and outcome in patients with sNPH were extracted independently after a thorough review of the results of each published article.
Summary measures included assessment of the frequency of patients with certain etiologies and the mean number of patients who improved after shunt placement.
Most identified publications combined both iNPH and sNPH, or excluded sNPH cases. Many of these studies did not differentiate among diagnostic, treatment, and outcome differences between these 2 entities. The design, patient selection criteria, outcome criteria, and conclusions of each study were analyzed. Outcome definitions and postoperative follow-up periods varied widely across studies. Several scales and scores were used to assess clinical improvement following shunt placement. The most common assessment of clinical improvement was defined as a decrease of at least 1 grade on the Stein and Langfitt grading scale, or equivalent improvement on other ordinal grading scales. 61 Marked improvement was defined as a decrease of at least 2 grades on the Stein and Langfitt grading scale, or equivalent improvement on other ordinal grading scales.
results study selection
The search generated approximately 3000 articles, of which 64 met our inclusion criteria (Table 1) .
2,5, 7-11, 14,16, 18, 19, 21-24, 26,27,29-33,36,38-50,52,54,56-63,65-71,73-83 A total of 1309 patients with sNPH were included. The mean number of patients per study was 21. Of the articles that mentioned the study design, 21 were prospective and 27 were retrospective. Fifty-nine studies reported the etiology of sNPH, 61 studies reported the diagnostic tests used to identify patients with NPH and the prognostic tests used to predict the outcomes of shunt placement, 46 studies reported the type of shunt used for management of NPH cases, and 38 studies mentioned the valve system used. The outcome specific to patients with sNPH after shunt surgery was reported in 35 studies.
etiology of sNPh
The etiology of sNPH was reported in 1208 patients (Table 2) . The most common cause of sNPH was SAH (n = 562, 46.5%). The second most common etiology resulting in sNPH was head trauma (n = 349, 29%). Other important etiologies included brain tumors and surgery for resection of intracranial malignancies in 75 patients (6.2%), meningoencephalitis in 61 patients (5%), cerebrovascular disease (CVD) in 55 patients (4.5%), and ICH in 49 patients (4%). Other etiologies made up for 5% of the causes of sNPH. These included mainly intracranial operations, radiosurgery, aqueductal stenosis, and Paget's disease.
Diagnosis of sNPh
The diagnosis of sNPH was based on a combination of clinical history, physical examination, and imaging studies. The NPH was considered to be secondary when an identifiable event occurred prior to the onset of symptoms and was judged to be directly related to the development of NPH. In most studies the diagnosis of NPH was established when patients presented with the classic symptoms of dementia, gait disturbance, and urinary incontinence accompanied by enlarged ventricles on brain imaging, with an Evans index of ≥ 0.3 (maximum width of the frontal horns divided by the transverse inner diameter of the cranium) and a "normal" CSF opening pressure measured by lumbar puncture in the lateral recumbent position (normal indicated a CSF pressure as low as < 150 mm H 2 O or as high as < 240 mm H 2 O). Additional diagnostic studies that were used to identify patients with sNPH included MRI in 14 studies and pneumoencephalography in 9 studies. In an attempt to differentiate patients who would benefit the most from shunting (patients with shunt-responsive NPH) from patients who would have less favorable outcomes (shunt-unresponsive patients), a multitude of prognostic tests were performed. The CSF tap test was used in 12 studies, cisternography was performed in 19 studies, cerebral blood flow determination was used in 20 studies, external lumbar drainage was performed in 4 studies, continuous ICP monitoring prior to shunt placement was used in 10 studies, and CSF dynamic studies with determination of conductance and resistance to CSF outflow using a lumbar infusion test were used in 24 studies. treatment of sNPh Ventriculoperitoneal (VP) shunting was used to treat patients with sNPH in 25 studies. Seven studies reported treatment with ventriculoatrial (VA) shunting, 10 studies reported that either VA or VP shunting was performed, and 2 studies reported that either VP or lumboperitoneal (LP) shunting was performed to manage sNPH cases. One study used LP shunting and another study used ventriculovenous shunting as the only treatment strategies. The treatment that was used to specifically manage sNPH was reported in 711 patients; 71.9% had insertion of a VP shunt, 24.4% had placement of a VA shunt, and 3.7% were treated with an LP shunt.
Three studies reported the use of a low-pressure valve system, 13 studies reported the use of a medium-pressure valve system, 11 studies used either a low-or a mediumpressure valve system, and 11 studies reported the use of programmable valves. The valve system specifically used in the management of sNPH was reported in 692 patients. Programmable valves were used in 47.8%, medium-pressure valves were used in 39.6%, and a low-pressure valve system was used in 12.6%.
outcome of NPh
Several studies combined the outcomes of patients with iNPH and those with sNPH after shunt placement, and could not be included in the outcome analysis. Outcomes were available in 708 patients with sNPH who underwent shunt placement (Table 3) . Of these patients, 527 showed clinical improvement (74.4%); excellent clinical improvement was reported in 58% of patients. The mean follow-up period after shunt placement was 13 months. In studies that further reported the outcome for the different etiologies of sNPH, 84.2% of patients with NPH secondary to SAH and 83% of patients with NPH secondary to head trauma had clinical improvement after shunting. A positive outcome after shunting was reported in 86.4% of patients with NPH secondary to brain tumors, in 75% of patients with NPH following meningoencephalitis, in 71.4% with NPH secondary to ICH, and in 64.7% of patients with NPH secondary to stroke and CVD. It is important to note that some of the studies that reported the lowest rates of improvement after shunting did not differentiate outcome based on etiology. The overall complication rate after shunt placement was 22%.
Discussion
In the 5 decades since the description of the syndrome of NPH, the understanding of the pathophysiological mechanism is still not fully elucidated, but our knowledge regarding the etiologies, diagnosis, prognosis, treatment, and assessment of patients who will benefit from shunt placement has evolved. Marmarou et al. reported that the "mixing" of cases of iNPH with cases of sNPH has led to considerable controversy regarding diagnostic and therapeutic strategies. 35 The differentiation between iNPH and sNPH has been highlighted by several authors as well, at least with regard to outcome after shunting. 4, 30, 71 Most of the recent work has focused on iNPH, whereas most of what we know regarding sNPH stems from studies originating from the 1960s to the 1990s. Differences in outcomes of iNPH and sNPH have been observed, with substantial improvement after shunting occurring in approximately 30%-50% of patients with no identifiable cause and in about 50%-70% of patients with sNPH. 72 The leading cause of sNPH (46.5%) was SAH. Chronic hydrocephalus develops in approximately 7%-37% of patients with SAH. 10 Fibrosis and adhesion at the level of the basal cisterns and the subarachnoid and arachnoid villi in patients with SAH can lead to the development of NPH. 25 Intracranial malignancies (6.2%) release proteinaceous products and cellular components into the CSF, which increases CSF viscosity and impairs its reabsorption at the level of the arachnoid granulations, leading to NPH. 51 There has been a wide variation in the incidence of posttraumatic hydrocephalus, mainly because of the different definitions used to identify this entity. The rate has been reported to be as low as 1% and as high as 29%. 36 Posttraumatic NPH accounted for 29% of sNPH cases. Similarly, posttraumatic NPH develops when there is impairment in the flow and absorption of CSF. Most etiologies lead to the development of sNPH as a result of 2 mechanisms. The first results from increased content of cells or proteins in the CSF (from SAH, meningitis, tumors, and so on), which causes clogging of CSF outflow and leads to obstruction from reduced absorption through the arachnoid granulations. This results in a decrease in conductance and an increase in resistance to CSF outflow. The second mechanism is due to leptomeningeal fibrosis, arachnoid adhesions, and scarring in the basal cisterns, leading to disturbances in CSF dynamics. 5, 53 There is an initial increase in CSF pressure that results in enlargement of the ventricles. The pressure normalizes afterward but the ventricular enlargement is maintained because of Laplace's law. 17 For NPH to be considered secondary, patients should have a well-established event preceding the occurrence of symptoms that is directly correlated with the development of the characteristic NPH symptoms and imaging findings. The time required for the development of NPH after SAH, trauma, meningitis, stroke, tumors, or intracranial surgery has not been established, but studies have suggested that symptoms may begin immediately after the inciting event, or there may be a delayed onset of a few months' duration. 80 As described in Wood et al., Hammes et al. reported that obliteration of subarachnoid spaces secondary to fibrosis begins as early as the 10th day after SAH. Ojemann et al. reported that 3 weeks may be sufficient for the development of NPH. 46 Marmarou et al. reported that hydrocephalus occurred within 2 weeks posttrauma in most patients, and within 1 month in all patients. 36 Wood et al. reported on 46 cases of sNPH and found that symptoms began either immediately or as late as 4 months after the event, with the majority of patients experiencing onset of disease within 1 month. 80 Hirai et al. reported that the mean preoperative period was significantly longer in iNPH (10 months vs 1 month). 21 Other studies have reported that NPH can still develop years after the initial event.
2, 30 In general, most patients develop NPH soon after the primary diseases. Onset of iNPH is usually gradual, with progressive worsening over time. Onset of sNPH may actually be acute or subacute. It is important to determine the time of onset because symptom duration affects the outcome of intervention. 12 Patients with sNPH do not always show the typical symptoms of dementia, gait abnormalities, and urinary incontinence as in the idiopathic counterpart, and may manifest other atypical symptoms, including seizures, altered consciousness, and motor and sensory deficits. This is because the primary diseases (SAH, traumatic brain injury, intracranial tumors, meningitis, stroke, and so on) often cause severe neurological deficits that might mask the typical NPH symptoms and make it more difficult to establish a diagnosis. 77 In certain cases, NPH might be suspected only when preexisting neurological deficits begin to deteriorate or when patients fail to have a satisfactory recovery following the initial event. Early diagnosis and shunt placement is essential because it may improve functional outcome and prevent further functional deterioration. Otherwise, functional recovery may be suboptimal. 10 Several tests have been proposed to accurately identify patients with NPH who will have the best outcome after shunting. These investigations include CT, MRI, isotope cisternography, pneumoencephalography, CSF withdrawal tests, cerebral blood flow measurements, continuous ICP monitoring, and infusion studies with evaluation of CSF dynamics. Whereas the importance of these preoperative evaluations has been widely established in the diagnosis of iNPH, the value of some of these tests remains questionable for sNPH. Stein and Langfitt reported that 80% of patients with sNPH had significant improvement, whereas significant improvement was only seen in 24% of iNPH cases. They reported that shunting should be performed directly in patients with sNPH and that preoperative tests are of little help in selecting this group of patients for surgery. 61 Børgesen and Gjerris identified a subset of patients with NPH who have a known etiology, short duration of symptoms, severe dementia and gait disturbances, and urinary incontinence who would benefit the most from shunt placement. They reported that these patients are most likely to improve without the need for excessive preoperative testing.
4,5
On the other hand, patients not fulfilling these criteria should be investigated using other preoperative tests. Wikkelsö et al. reported that NPH after SAH has a good prognosis, and that these patients present typical changes on CT and radionuclide cisternography and represent a minor diagnostic problem as compared with patients with iNPH. 79 Gjerris et al. reported that CSF dynamic studies can be used to predict outcomes in patients with sNPH after SAH, especially in patients with high resistance to CSF outflow.
14 Similarly, Marmarou et al. suggested that CSF dynamic studies can help in establishing the diagnosis and prognosis of patients with sNPH that results from head trauma. 36 When patients display atypical symptoms of NPH, CSF dynamic studies can help in deciding whether to perform shunt placement for those with suspected sNPH. 78 Responsiveness to shunting procedures constitutes the most important difference between idiopathic and secondary forms of NPH. Of the patients with sNPH, 74.4% were found to have improvement in clinical status after shunting. Børgesen reported that of 31 patients without a known etiology, only 42% improved 1 year after shunting, whereas 72% of patients with a known etiology had improved. The trend toward better results in patients with a known etiology was significant (p < 0.01). 4 In the same study it was reported that both patients with iNPH and those with sNPH had similar pretreatment clinical status, and that the observed difference in outcome cannot be attributed to differences in the initial clinical status. Vanneste et al. reported that marked improvement occurred in 52% of patients with sNPH, lowering to 15% when only patients with iNPH were considered. 70 They further conducted a literature review of 1047 patients in which they showed that studies in patients with iNPH found marked improvement in 33%, whereas studies with mixed patients found marked improvement in 50%. They concluded that the etiology of NPH has a significant effect on outcome. Larsson et al. reported that patients with sNPH had a better prognosis than did those with iNPH (94% SAH, 79% posttraumatic, 77% idiopathic). 30 The duration of preoperative symptoms has been reported to be a significant factor in the prognosis of NPH. 16, 30 Patients with sNPH present with a shorter duration of preoperative symptoms, because the presence of a known etiology can lead to an earlier investigation and detection of NPH symptoms. Similarly, Thomsen et al. reported that patients with NPH of a known cause had a better outcome than patients with iNPH, and that disease duration of less than 12 months was an important factor for successful outcome. They reported that patients with sNPH usually have a more abrupt onset of dementia, whereas patients with iNPH usually experience gradual deterioration. 65 Wood et al. reported that symptom duration of less than 6 months is a good prognostic factor for improvement after shunting. However, their study was one of the few to conclude that etiology did not have an important prognostic value. 80 Other studies have further suggested that patients with sNPH may have a more favorable shunt outcome than patients with iNPH, because patients with iNPH may have brain atrophy in addition to hydrocephalic features, whereas sNPH patients only have a CSF circulatory disorder. 64, 67 Although our results support the separation of iNPH and sNPH based on outcome, iNPH and sNPH do not represent separate entities; rather, they represent a clinical syndrome associated with a subset of patients with acquired hydrocephalus-patients of different ages with different etiologies and vastly different pathophysiology. Both iNPH and sNPH represent a disorder of CSF flow and absorption, although iNPH may be associated with other factors including white matter ischemic changes, increased transmantle pressure, asymptomatic fibrosing meningitis, and insufficiency of the transcortical subarachnoid space.
20,37
Both VP and VA shunting have been used successfully in the management of sNPH. The most important factor to consider in the treatment of patients with sNPH is early intervention. Wen et al. reported that shunt placement should be performed within 6 months of the onset of posttraumatic hydrocephalus. 78 Some studies that used programmable valves observed a higher rate of reprogramming in patients with iNPH. Zemack and Romner reported that in the iNPH group 49% of patients required valve adjustments, versus 32.4% of patients with sNPH (because of overdrainage, underdrainage, and subdural hematoma). 83 Similarly, Yamashita et al. reported that shunt reprogramming was more frequently performed in patients with iNPH than in patients with sNPH after SAH. 82 The best response to treatment was observed in the SAH, head trauma, and intracranial malignancy groups. These patients may benefit the most from shunt surgery for sNPH.
Patients with sNPH who require surgical shunt placement are often being treated with anticoagulation and antiplatelet agents to manage the primary disease, including stroke or endovascular interventions for aneurysm treatment in patients with SAH, or these patients may be on anticoagulation therapy for the management of other comorbid conditions (atrial fibrillation, deep venous thrombosis, valvular heart disease, and so on). Whether shunting should be performed in these patients is controversial. 13 The benefits-to-risk ratio should be assessed for each individual. The feared complications of shunting in patients on anticoagulation therapy include ICH, subdural hematoma, abdominal bleeding, and thromboembolic complications after discontinuation of antithrombotic agents. Goodwin et al. reported a low rate of subdural hematoma (6.7%) in patients on long-term warfarin therapy, and they observed no thromboembolic complications when they stopped warfarin prior to shuting. 15 They concluded that anticoagulation was not a contraindication for shunting in patients with NPH. Perioperative management of antithrombotic therapy can be accomplished safely, and anticoagulation treatment should not prevent the placement of a shunt in patients with sNPH.
The combination of several factors supports the existence of sNPH, including the facts that sNPH can occur in any age group, versus iNPH, which occurs most commonly in the elderly population; that an acute or subacute onset is associated with sNPH following the suspected etiology, versus a slow, gradual onset in patients with iNPH; that typical symptoms of NPH may not always be present with sNPH and atypical symptoms may occur; and that there are higher rates of improvement after shunt placement in patients with sNPH compared with iNPH, which plays an important role in patient selection for shunting. Although we evaluated the various sNPH etiologies, further separation of cases based on etiology is not clearly supported from our data and requires further studies.
The limitations of this review relate to paucity of the literature on the topic of sNPH; the search strategy with the inclusion of smaller studies and older studies; and the inclusion of heterogeneous studies that have a wide variation in the size, population, methodology (both prospective and retrospective studies), and outcome definition. In addition, the lack of randomization of the included studies, with each one having its own reporting bias, should be highlighted as well. It is important to assess the likely extent of the bias and its potential impact on the conclusions. Nevertheless, for this rarely discussed subject, Class I or II evidence is difficult to obtain. This review paper evaluates patients with one clinical pattern of acquired hydrocephalus (NPH) and cannot be generalized to the entire acquired hydrocephalus population. Because of the limitations of this review, further studies are recommended.
Conclusions
Secondary NPH does indeed exist and should be differentiated from iNPH based on outcome as well as clinical, pathophysiological, and epidemiological characteristics but should not be considered as a separate entity. Evaluation of patients with NPH to identify a known cause is recommended because the response to treatment varies considerably. Although clinical presentation is often the same, a multitude of primary etiologies can lead to the development of sNPH. The most common etiologies of sNPH include SAH, traumatic brain injury, intracranial malignancies, meningitis, and stroke. Further studies are required to investigate differences in management and outcome among the diverse etiologies of sNPH. 
